Centralyze is an Investment Platform for high-value innovative biotechnologies, each of which specifically addresses the world's major diseases.
We custom builds every Centralyze Company to contain world-leading research and development teams.
We bring confidence to investors by implementing our unique Centralyze Process: Originate, Engage, Capitalise and Commercialise.
Centralyze performs due diligence of select institutional IP through independent scientific, patent and market analysis.
Centralyze develops with seed investment, commercialisation plan development, assignment of IP, corporate structuring and exit partner engagement.
Approved investors are invited to invest in the equity of our portfolio companies.
Milestone-based investment allows for a broad range of investors to come in at their preferred research stage and risk level.
Our portfolio companies receive back office and ongoing commercialisation support.
Investors are supported by company oversight, reporting and exit opportunity identification as the commercialisation concludes.
Upon successful completion of their commercialisation plan, each portfolio company is exited, whether it be a pharmaceutical company, venture capital, or through an IPO.